<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084019</url>
  </required_header>
  <id_info>
    <org_study_id>A5201</org_study_id>
    <secondary_id>10096</secondary_id>
    <secondary_id>ACTG A5201</secondary_id>
    <nct_id>NCT00084019</nct_id>
  </id_info>
  <brief_title>Atazanavir/Ritonavir Maintenance Therapy</brief_title>
  <official_title>A Prospective, Open-Label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Long-term side effects, the expense of medications, and the difficulty of taking medications&#xD;
      continuously for long periods of time are all problems with complicated anti-HIV drug&#xD;
      regimens. The purpose of this study is to determine whether two drugs, atazanavir (ATV) and&#xD;
      ritonavir (RTV), will control HIV infection when taken together without any other anti-HIV&#xD;
      drugs after 48 weeks of viral suppression.&#xD;
&#xD;
      Hypothesis: Simplified maintenance therapy with ATV and RTV alone after virologic suppression&#xD;
      does not markedly increase the risk of virologic failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The expense, difficulty, and long-term adverse events associated with sustained adherence to&#xD;
      combination antiretroviral therapy emphasize the need for simpler, alternative treatment&#xD;
      strategies for HIV infection. Studies have shown that single protease inhibitor (PI)&#xD;
      maintenance therapy may provide sufficient virologic suppression while reducing the risk of&#xD;
      nucleoside reverse transcriptase inhibitor (NRTI)-associated metabolic complications.&#xD;
      However, it is not known whether ritonavir-boosted atazanavir (ATV/RTV) maintenance therapy&#xD;
      would be effective in controlling HIV replication in the genital compartments and whether&#xD;
      viral load testing by blood collection would be effective in detecting elevated levels of HIV&#xD;
      in the genital compartments. This study will determine whether simplified maintenance therapy&#xD;
      with ATV/RTV after 48-week virologic suppression will increase the likelihood of virologic&#xD;
      failure.&#xD;
&#xD;
      This study will last 54 weeks. Participants will undergo an electrocardiogram (EKG) at&#xD;
      screening. At study start, participants will switch from their current PIs to ATV/RTV and&#xD;
      stay on their current NRTIs until Week 6, when they will discontinue their NRTIs and remain&#xD;
      on a maintenance regimen of ATV/RTV alone for the duration of the study. Study visits will&#xD;
      take place at Weeks 3 and 6, then every 4 weeks until Week 30, then every 8 weeks until the&#xD;
      end of the study at Week 54. Medication assessment, physical exam, and blood work will occur&#xD;
      at each study visit. At Week 30, viral load will be measured in the genital secretions of&#xD;
      both male and female study participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic failure, defined as 2 consecutive viral load measurements of 200 copies/ml or greater, at or before Week 30 (24 weeks on ATV/RTV alone)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3 and 4 laboratory abnormalities and signs and symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment discontinuation because of toxicity or intolerance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virologic failure at or before Week 54</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral load determined by modified ultrasensitive RT-PCR assay</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minor PI variants at virologic failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol, high-density lipoprotein (HDL) cholesterol, calculated low-density lipoprotein (LDL) cholesterol, and triglycerides</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 cell count and percentages at Weeks 30 and 54</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self-reported adherence scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma drug levels characterized by Cmin and AUC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>detectable viral load in the genital compartment at Week 30</measure>
  </secondary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  On first antiretroviral regimen, including at least 2 NRTIs and 1 PI, for at least 48&#xD;
             weeks immediately prior to study entry&#xD;
&#xD;
          -  CD4 count of 250 cells/mm3 or greater&#xD;
&#xD;
          -  Viral load less than 50 copies/ml within 30 days prior to entry&#xD;
&#xD;
          -  Willing to use acceptable methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or prior use of an NNRTI&#xD;
&#xD;
          -  Certain PI mutations&#xD;
&#xD;
          -  Hepatitis B infection within 90 days prior to study entry&#xD;
&#xD;
          -  Certain therapies or medications within 30 days prior to study entry&#xD;
&#xD;
          -  Heartbeat abnormalities or symptoms potentially related to heart block, such as&#xD;
             unexplained fainting, dizziness, or palpitations, occurring within 180 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  Drug or alcohol use or dependence that would interfere with adherence to the study&#xD;
             requirements&#xD;
&#xD;
          -  Serious illness requiring systemic treatment or hospitalization until the participant&#xD;
             either completes therapy or has been clinically stable on therapy for at least 14 days&#xD;
             prior to study entry&#xD;
&#xD;
          -  Allergy or sensitivity to study medications or their formulations&#xD;
&#xD;
          -  Current involuntarily incarceration for treatment of either a mental or physical&#xD;
             illness&#xD;
&#xD;
          -  Treatment for an active AIDS-defining opportunistic infection within 30 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Swindells, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-5350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Iowa Healthcare, Div. of Infectious Diseases</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-9500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VAMC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1514</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JP, Holohan MK, Leavitt R, Boone G, Richman DD. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998 Oct 29;339(18):1261-8.</citation>
    <PMID>9791141</PMID>
  </reference>
  <reference>
    <citation>Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998 Oct 29;339(18):1269-76.</citation>
    <PMID>9791142</PMID>
  </reference>
  <reference>
    <citation>Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 1998 Jul 18;352(9123):185-90.</citation>
    <PMID>9683207</PMID>
  </reference>
  <reference>
    <citation>Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker UA, Vernazza PL. Ritonavir boosted indinavir treatment as a simplified maintenance &quot;mono&quot;-therapy for HIV infection. AIDS. 2004 Apr 9;18(6):955-7.</citation>
    <PMID>15060447</PMID>
  </reference>
  <reference>
    <citation>Kelly M. Induction-maintenance antiretroviral strategies to reduce long-term toxicity. J HIV Ther. 2003 Feb;8(1):11-4. Review.</citation>
    <PMID>12840709</PMID>
  </reference>
  <results_reference>
    <citation>Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006 Aug 16;296(7):806-14.</citation>
    <PMID>16905786</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 4, 2004</study_first_submitted>
  <study_first_submitted_qc>June 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2004</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

